TOP TEN perturbations for 38872_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38872_at
Selected probe(set): 205791_x_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38872_at (205791_x_at) across 6674 perturbations tested by GENEVESTIGATOR:
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenosquamous carcinoma; primary)
Relative Expression (log2-ratio):2.8061934Number of Samples:2 / 4
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; adenosquamous carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenosquamous carcinoma of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; basaloid carcinoma; primary)
Relative Expression (log2-ratio):2.571332Number of Samples:2 / 3
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; basaloid carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary basaloid carcinoma of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):2.543867Number of Samples:2 / 22
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; non-small cell carcinoma; primary) / lung cancer study 1 (PDX; large cell carcinoma, NOS; primary)
Relative Expression (log2-ratio):2.4951086Number of Samples:2 / 4
| Experimental | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; large cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary large cell carcinoma, NOS of the lung (subcutaneously implanted). |
lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) / lung cancer study 1 (PDX; non-small cell carcinoma; primary)
Relative Expression (log2-ratio):-2.4195127Number of Samples:43 / 2
| Experimental | lung cancer study 1 (PDX; squamous cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary squamous cell carcinoma, NOS of the lung (subcutaneously implanted). | |
| Control | lung cancer study 1 (PDX; non-small cell carcinoma; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary non-small cell carcinoma of the lung (subcutaneously implanted). |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.2214422Number of Samples:2 / 2
| Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
| Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
| Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):2.0520601Number of Samples:4 / 4
| Experimental | B-CLL study 11 (rolipram) |
| Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
| Control | rolipram study 4 (normal B-cell; 20uM) |
| MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
AsPC-1 / BxPC-3
Relative Expression (log2-ratio):-2.015133Number of Samples:3 / 3
| Experimental | AsPC-1 |
| Human xenograft derived metastatic cancer cell line derived from mouse xenografts initiated with metastatic cells from the ascites derived from a 62 years old female Caucasian patient with pancreatic adenocarcinoma. Synonyms:AsPc-1; Aspc-1; ASPC-1; As-PC1; ASPC1; AsPC1; Aspc1; AsPc1 Cellosaurus code: | |
| Control | BxPC-3 |
| Human pancreatic adenocarcinoma cell line derived from a 61 years old female patient. Synonyms:BxPc-3; BXPC-3; Bx-PC3; BXPC3; BxPC3; BxPc3 Cellosaurus code: |
brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) / untreated HCT 116 DICER1(-/-) cell sample
Relative Expression (log2-ratio):1.9846287Number of Samples:3 / 3
| Experimental | brefeldin A study 1 (0.5ug/ml; HCT 116 DICER1(-/-)) |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 was treated with 0.5 ug/ml brefeldin-A for 24 hours in McCOYs 5A medium supplemented with 10% heat inactivated FBS. ATC code:--- | |
| Control | untreated HCT 116 DICER1(-/-) cell sample |
| Derived human colon carcinoma cell line HCT 116 DICER1(-/-) with knockout DICER gene in exon 5 by was grown in McCOYs 5A medium supplemented with 10% heat inactivated FBS. |
conditioned medium study 1 (HS5) / untreated monocyte (CD14+) sample
Relative Expression (log2-ratio):1.8111753Number of Samples:2 / 2
| Experimental | conditioned medium study 1 (HS5) |
| CD14+ monocytes treated with HS5 conditioned medium (CM) for 48h. | |
| Control | untreated monocyte (CD14+) sample |
| Untreated CD14+ monocytes from two different donors. |